Trial Profile
A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary) ; Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Sep 2008 New trial record.